Document is current
Any future updates will be listed below
-
Authors
Lu, Xi https://orcid.org/0000-0002-1650-9974
Maturi, Naga Prathyusha https://orcid.org/0000-0002-7726-8617
Jarvius, Malin
Yildirim, Irem https://orcid.org/0000-0003-3602-5544
Dang, Yonglong
Zhao, Linxuan
Xie, Yuan
Tan, E-Jean https://orcid.org/0000-0002-4631-174X
Xing, Pengwei
Larsson, Rolf
Fryknäs, Mårten
Uhrbom, Lene https://orcid.org/0000-0001-8595-5698
Chen, Xingqi https://orcid.org/0000-0002-5657-2839
-
Funding
Funding for this research was provided by:
Cancerfonden (15 0877, 18 0763, 21 1518, 21 1449)
Vetenskapsrådet (2018-02906, 2017-02074)
- License Information
-
More Information
Article History
Received: 6 February 2021
Accepted: 7 April 2022
First Online: 25 April 2022
Competing interests
: R.L. and M.F. are minor shareholders of Oncopeptides AB and have previously received unrestricted grants from the company. The remaining authors declare no competing interests.
